Clinical Trials Logo

Hand-foot Syndrome clinical trials

View clinical trials related to Hand-foot Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03173365 Terminated - Hand-foot Syndrome Clinical Trials

The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients

BRIMOCAN
Start date: July 10, 2017
Phase: Phase 2
Study type: Interventional

Comparative analysis of the severity of Hand-Foot-Syndrome (HFS) of palms treated with brimonidine tartrate gel or with standard care Urea 10% containing lotion in cancer patients receiving antineoplastic therapy to show a preventive effect of cutaneous brimonidine treatment on severity of HFS symptoms.

NCT ID: NCT00827580 Terminated - Breast Cancer Clinical Trials

Eniluracil Hand Foot Syndrome

Start date: January 2009
Phase: Phase 1
Study type: Interventional

A pilot study of eniluracil containing ointment for prevention of hand foot syndrome (HRS) following capecitabine (Xeloda).

NCT ID: NCT00767689 Terminated - Clinical trials for Hand and Foot Syndrome

Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy

Start date: March 21, 2006
Phase: N/A
Study type: Interventional

Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and feet, a condition called Hand and Foot syndrome. patients , starting capecitabine chemotherapy for their cancer, will participate in this study at John H. Stroger Jr. Hospital of Cook County. They will be randomized to receive either vitamin B6 or a placebo. investigators and patients will be blinded to the intervention.

NCT ID: NCT00751101 Terminated - Breast Cancer Clinical Trials

Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer

Start date: August 20, 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Nicotine patches may reduce hand-foot syndrome in patients receiving capecitabine for metastatic breast cancer. It is not yet known which nicotine patch regimen may be more effective in reducing hand-foot syndrome. PURPOSE: This randomized clinical trial is studying which schedule of using nicotine patches is more effective in reducing hand-foot syndrome in patients who are receiving capecitabine for metastatic breast cancer.

NCT ID: NCT00486213 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer

Start date: June 2007
Phase: Phase 3
Study type: Interventional

RATIONALE: Pyridoxine may help prevent hand-foot syndrome caused by capecitabine in patients with cancer. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome in patients with cancer. PURPOSE: This randomized phase III trial is studying pyridoxine to see how well it works compared with a placebo in preventing hand-foot syndrome caused by capecitabine in patients with cancer.